FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1525-1527 October 6, 2005 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Topol, E. J. Related Article PubMed Citation

To the Editor: In his Perspective article, Topol (July 14 issue)¹ discusses current clinical practice with respect to nesiritide. According to the Food, Drug, and Cosmetic Act, drug approval can be withdrawn when "new evidence of clinical experience, not contained in such application or not available to the Secretary until after such application was approved, or tests by new methods, or tests by methods not deemed reasonably applicable when such application was approved, evaluated together with the evidence available to the Secretary when the application was approved, shows that such drug is not shown to be safe for use under . . . [Full Text of this Article]

Related Letters:

Treatment for Rheumatic Disorders
Tindall E. A., Fox D. A.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1322-1323, Mar 23, 2006. Correspondence

This article has been cited by other articles:

• Tindall, E. A., Fox, D. A. (2006). Treatment for rheumatic disorders.. NEJM 354: 1322-1323 [Full Text]